Catalyst
Slingshot members are tracking this event:
Amedica Receives FDA Clearance for Additional Valeo II Lateral Lumbar Interbody Fusion Device Offerings
Do you think this event is important to the companies below? How will it affect their stock price?
Related Companies | Importance
|
Impact on Stocks
|
||||
---|---|---|---|---|---|---|
AMDA |
|
|
Additional Information
"I'm delighted to announce the recent FDA clearance of our expanded silicon nitride lateral lumbar implant offerings," said Dr. Sonny Bal, Chairman and Chief Executive Officer. "It's estimated that lateral lumbar procedures will remain one of the fastest growing interbody fusion segments over the next five years. The minimally invasive nature of the procedure provides patients with benefits such as less blood loss, smaller incisions and shorter hospital and intraoperative times. We believe these clinical benefits, coupled with our unique silicon nitride biomaterial will lead to an improved continuum of care for individuals."
Slingshot Insights Explained
Catalyst Date
Occurred on:
Aug 24, 2016
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Valeo Ii, Lateral Lumbar Interbody Fusion Device, Medical Grade Silicon Nitride Ceramic